RxDoctor Payments Data

Patrick Boler, MD

Dermatology · Clinton, MSNPI 1225390719

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Galderma Laboratories, L.p. accounts for 61.5% of it on its own, with 39 other manufacturers making up the rest. 2025 is the largest year on record at $30,370, more than ten times the $1,565 reported in 2019. Among dermatology clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$44,483in general payments, 2019–2025

Across 903 payments — averaging $49.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$27K
  • AbbVie$3K
  • Johnson & Johnson$2K
  • Novartis$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • UCB, Inc.$1K
  • plus $8K from 34 others

What the payments were for

  • Consulting fees$6952%
  • Speaking & faculty fees$25,82458%
  • Travel & lodging$3461%
  • Food & beverage$17,29139%
  • Education$3281%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,483 in reported general payments places this provider in the 90th percentile of 78 dermatology providers in Mississippi.

See all dermatology providers in Mississippi

Medicare billing

Part B allowed, 2024
$742,625
Medicare patients
1,028
Services billed
9,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast21$101,717
RinvoqUpadacitinib16$98,705
Dupixent PenDupilumab15$69,682
Fluorouracil72$4,722
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc167$4,711
Acitretin15$3,981
Desonide43$3,400
Mycophenolate Mofetil25$3,192
Ketoconazole106$2,201
Fluocinolone AcetonideFluocinolone/Shower Cap34$1,548
Triamcinolone Acetonide101$1,246
Doxycycline Monohydrate53$1,142
Mometasone Furoate66$1,114
Clobetasol Propionate31$932
Fluocinolone Acetonide Oil16$698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$196$101,71721 claims
AbbVieRinvoq$3,366$98,70516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 78 dermatology providers in Mississippi.

Other dermatology in Clinton

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →